MCID: TNG003
MIFTS: 63

Tongue Cancer

Categories: Rare diseases, Cancer diseases, Oral diseases

Aliases & Classifications for Tongue Cancer

MalaCards integrated aliases for Tongue Cancer:

Name: Tongue Cancer 12 49 51 14
Tongue Carcinoma 49 51 69
Malignant Neoplasm of Tongue 12 69
Tongue Neoplasms 41 69
Malignant Neoplasm of Anterior Two-Thirds of Tongue, Part Unspecified 12
Malignant Neoplasm of Tip and/or Lateral Border of Tongue 12
Malignant Neoplasm of Anterior 2/3 of Tongue Unspecified 12
Malignant Neoplasm of Tip and Lateral Border of Tongue 12
Malignant Neoplasm of Tongue, Tip and Lateral Border 12
Malignant Neoplasm of Ventral Tongue Surface Nos 12
Malignant Tumor of Anterior Two-Thirds of Tongue 12
Malignant Neoplasm of Junctional Zone of Tongue 12
Malignant Neoplasm of Mobile Part of Tongue Nos 12
Malignant Neoplasm of Ventral Surface of Tongue 12
Malignant Neoplasm of Dorsal Surface of Tongue 12
Malignant Neoplasm of Fixed Part of Tongue Nos 12
Malignant Neoplasm of Other Sites of Tongue 12
Tongue Neoplasm Malignant Stage Unspecified 12
Malignant Neoplasm of Dorsum of Tongue Nos 12
Malignant Tumor of Mobile Part of Tongue 12
Malignant Neoplasm of Dorsal Tongue Nos 12
Malignant Neoplasm of Border of Tongue 12
Malignant Neoplasm of Base of Tongue 12
Malignant Neoplasm of Lingual Tonsil 12
Malignant Tumor of Posterior Tongue 12
Malignant Neoplasm of Tongue, Nos 12
Malignant Tumor of Base of Tongue 12
Malignant Tumor of Lingual Tonsil 12
Malignant Neoplasm of Tongue Nos 12
Malignant Tumor of Tongue 12
Tongue Neoplasm 72

Classifications:



Summaries for Tongue Cancer

MalaCards based summary : Tongue Cancer, also known as tongue carcinoma, is related to squamous cell carcinoma of the oral tongue and periodontitis, and has symptoms including glossalgia An important gene associated with Tongue Cancer is MMP8 (Matrix Metallopeptidase 8), and among its related pathways/superpathways are GPCR Pathway and Endometrial cancer. The drugs Nicotine and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include tongue, tonsil and lung, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 72 Oral cancer, also known as mouth cancer, is a type of head and neck cancer and is any cancerous tissue... more...

Related Diseases for Tongue Cancer

Diseases related to Tongue Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma of the oral tongue 30.2 CCND1 CDH1
2 periodontitis 29.5 MMP2 MMP8 MMP9
3 squamous cell carcinoma 28.5 CCND1 CDH1 CDKN1A CDKN2A MMP2 MMP9
4 papilloma 28.4 CCND1 CDKN1A CDKN2A KRT13 TP53
5 oral cancer 27.9 CCND1 CDH1 CDKN2A KRT13 MMP2 MMP9
6 tongue squamous cell carcinoma 27.8 BMI1 CDH1 CDKN2A CTNNB1 MMP2 MMP9
7 oral squamous cell carcinoma 26.3 CCND1 CDH1 CDKN1A CDKN2A CTNNB1 FAM168A
8 lung cancer 26.2 CCND1 CDH1 CDKN1A CDKN2A CTNNB1 MMP2
9 esophageal cancer 25.8 BMI1 CCND1 CDH1 CDKN1A CDKN2A CTNNB1
10 nasopharyngeal carcinoma 25.5 BMI1 CCND1 CDH1 CDKN2A CTNNB1 KRT13
11 cerebral convexity meningioma 10.6 CDH1 TP53
12 actinic cheilitis 10.5 CDKN1A TP53
13 vulvar intraepithelial neoplasia 10.5 MMP2 TP53
14 adult hepatocellular carcinoma 10.5 CTNNB1 TP53
15 invasive bladder transitional cell carcinoma 10.5 CDKN1A TP53
16 bladder transitional cell papilloma 10.5 CDKN1A TP53
17 atypical follicular adenoma 10.5 CDKN1A TP53
18 large intestine adenocarcinoma 10.5 CDH1 CTNNB1
19 female reproductive endometrioid cancer 10.5 CTNNB1 TP53
20 lip cancer 10.4 CDKN1A TP53
21 goblet cell carcinoid 10.4 CDH1 CTNNB1
22 extracranial arteriovenous malformation 10.4 MMP2 MMP9
23 focal myositis 10.4 MMP2 MMP9
24 malignant ovarian surface epithelial-stromal neoplasm 10.4 CDH1 MMP2 TP53
25 ovary epithelial cancer 10.4 CDH1 MMP2 TP53
26 serous cystadenocarcinoma 10.4 CDKN1A MMP2 TP53
27 spastic entropion 10.4 MMP2 MMP9
28 lentigo maligna melanoma 10.4 MMP2 MMP9
29 villous adenocarcinoma 10.4 MMP2 MMP9
30 signet ring cell adenocarcinoma 10.4 CDH1 CTNNB1 TP53
31 colorectal adenocarcinoma 10.3 CDH1 CTNNB1 TP53
32 acute transverse myelitis 10.3 MMP2 MMP9
33 lobular neoplasia 10.3 CDH1 CTNNB1 PRLR
34 brain stem astrocytic neoplasm 10.3 CDKN2A TP53
35 amaurosis fugax 10.3 MMP8 MMP9
36 senile ectropion 10.3 MMP2 MMP9
37 colon adenocarcinoma 10.3 CDH1 CDKN1A CTNNB1
38 squamous cell carcinoma of the oropharynx 10.3 CDKN2A TP53
39 extramedullary plasmacytoma 10.3 CCND1 CDKN1A
40 spitz nevus 10.3 CDKN2A TP53
41 brain glioblastoma multiforme 10.3 MMP9 TP53
42 esophagus squamous cell carcinoma 10.3 CCND1 CDH1
43 non-proliferative fibrocystic change of the breast 10.3 CCND1 TP53
44 cheilitis 10.3 CDKN1A MMP9 TP53
45 internal hemorrhoid 10.3 MMP2 MMP9
46 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
47 microcystic meningioma 10.2 CDH1 MMP2 MMP9
48 lung giant cell carcinoma 10.2 CDH1 MMP2 MMP9
49 squamous cell carcinoma of the larynx 10.2 CDKN2A TP53
50 ureteral obstruction 10.2 CTNNB1 TP53 VEGFC

Comorbidity relations with Tongue Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Tongue Cancer:



Diseases related to Tongue Cancer

Symptoms & Phenotypes for Tongue Cancer

UMLS symptoms related to Tongue Cancer:


glossalgia

MGI Mouse Phenotypes related to Tongue Cancer:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.23 CCND1 CDKN2A CDH1 CTNNB1 CDKN1A VEGFC
2 cardiovascular system MP:0005385 10.18 CDKN1A CCND1 CDKN2A CDH1 TP53 VEGFC
3 growth/size/body region MP:0005378 10.18 CDKN1A CCND1 CDKN2A CDH1 TP53 MMP9
4 immune system MP:0005387 10.17 CCND1 CDKN2A CDH1 CTNNB1 CDKN1A VEGFC
5 digestive/alimentary MP:0005381 10.11 CCND1 CDKN2A CDH1 CTNNB1 CDKN1A TERT
6 neoplasm MP:0002006 10.11 CCND1 CDKN2A CDH1 CTNNB1 CDKN1A PRLR
7 endocrine/exocrine gland MP:0005379 10.1 CDKN1A CCND1 CDKN2A CDH1 TP53 CTNNB1
8 integument MP:0010771 10.01 CDKN1A CCND1 CDKN2A CDH1 TP53 CTNNB1
9 nervous system MP:0003631 9.97 CDKN1A CCND1 CDKN2A TP53 MMP9 CTNNB1
10 reproductive system MP:0005389 9.91 CDKN1A CCND1 CDKN2A CDH1 CTNNB1 PRLR
11 respiratory system MP:0005388 9.76 CCND1 CDKN2A CTNNB1 CDKN1A MMP2 TERT
12 skeleton MP:0005390 9.61 CDKN1A CCND1 CDKN2A CTNNB1 PRLR MMP2
13 vision/eye MP:0005391 9.23 CDKN1A CCND1 CDKN2A CTNNB1 TP53 PRLR

Drugs & Therapeutics for Tongue Cancer

Drugs for Tongue Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 89594 942
2 Liver Extracts Phase 4,Phase 2,Phase 1
3 Central Nervous System Stimulants Phase 4
4 Cholinergic Agents Phase 4,Phase 2,Phase 3
5 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
6 Nicotinic Agonists Phase 4
7 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
8 Autonomic Agents Phase 4,Phase 2,Phase 3
9
Cisplatin Approved Phase 2, Phase 3, Phase 1 15663-27-1 2767 441203 84093
10
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
11
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
12
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
13
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
14
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
15
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
16
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
17
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
18
Docetaxel Approved May 1996, Investigational Phase 2, Phase 3, Phase 1 114977-28-5 148124 9877265
19 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
20 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
21 Anti-HIV Agents Phase 3,Phase 2
22 Anti-Infective Agents Phase 3,Phase 2,Phase 1
23 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
24 Antimetabolites Phase 3,Phase 2,Phase 1
25 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
26 Interleukin-2 Phase 3
27 Anti-Retroviral Agents Phase 3,Phase 2
28 Antimitotic Agents Phase 2, Phase 3, Phase 1
29 Antiviral Agents Phase 3,Phase 2
30
Histamine Phosphate Phase 3 51-74-1 65513
31 Mitogens Phase 3,Phase 2,Phase 1
32 Vaccines Phase 3,Phase 1
33 Histamine Antagonists Phase 3
34 Antibodies, Monoclonal Phase 2, Phase 3, Phase 1
35 Antidepressive Agents Phase 3
36 Antidepressive Agents, Tricyclic Phase 3
37 Immunoglobulins Phase 2, Phase 3, Phase 1
38 Psychotropic Drugs Phase 3
39 Antibodies Phase 2, Phase 3, Phase 1
40 Endothelial Growth Factors Phase 3
41
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
42
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
43
Indinavir Approved Phase 2 150378-17-9 5362440
44
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
45
Zinc Approved, Investigational Phase 2 7440-66-6 32051 23994
46
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
47
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
48
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
49
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
50
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860

Interventional clinical trials:

(show top 50) (show all 102)

# Name Status NCT ID Phase Drugs
1 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
3 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
4 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
5 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
6 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
7 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
8 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Recruiting NCT00956007 Phase 3
9 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
10 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
11 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
12 CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT Unknown status NCT01760811 Phase 1, Phase 2 Erbitux,merck serono
13 Trial of E10A in Head and Neck Cancer Unknown status NCT00634595 Phase 2 E10A;Cisplatin;Paclitaxel
14 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00833261 Phase 2 cetuximab;cisplatin
15 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
16 Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Unknown status NCT00625937 Phase 2 cisplatin;docetaxel;tegafur-gimeracil-oteracil potassium
17 Cetuximab and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Oropharynx Cancer That Can Be Removed by Surgery Completed NCT00665392 Phase 2 cisplatin;docetaxel;fluorouracil;Cetuximab
18 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
19 Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer Completed NCT01084083 Phase 2 Paclitaxel;Cisplatin
20 Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Completed NCT00064103 Phase 1, Phase 2
21 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
22 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
23 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
24 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
25 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
26 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
27 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
28 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
29 Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
30 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2 Soy Isoflavones
31 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2 Temsirolimus
32 Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery Completed NCT01333085 Phase 1, Phase 2 carboplatin;RAD001;paclitaxel
33 Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Completed NCT01195922 Phase 1, Phase 2 Sirolimus
34 Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer Completed NCT00875849 Phase 2 cisplatin
35 Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Cisplatin, and Cetuximab Given Together With Radiation Therapy in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00851877 Phase 1, Phase 2 cisplatin;paclitaxel albumin-stabilized nanoparticle formulation
36 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
37 Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00423930 Phase 2 cisplatin
38 Zinc Supplements in Lowering Cadmium Levels in Smokers Completed NCT00376987 Phase 2
39 High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer Recruiting NCT03008330 Phase 1, Phase 2
40 Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer Recruiting NCT02849379 Phase 1, Phase 2
41 A Dye for the Detection of Cancer of the Tongue and Mouth Recruiting NCT03085147 Phase 1, Phase 2 Olaparib
42 Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study Recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
43 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
44 Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN) Active, not recruiting NCT01312350 Phase 2 neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT
45 Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer Active, not recruiting NCT02254278 Phase 2 Cisplatin
46 Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting NCT02035527 Phase 1, Phase 2 sorafenib tosylate;cisplatin;docetaxel
47 PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
48 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Active, not recruiting NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
49 Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Active, not recruiting NCT01175980 Phase 2 Vorinostat
50 Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer Not yet recruiting NCT03181035 Phase 1, Phase 2 Pimonidazole

Search NIH Clinical Center for Tongue Cancer

Cochrane evidence based reviews: tongue neoplasms

Genetic Tests for Tongue Cancer

Anatomical Context for Tongue Cancer

MalaCards organs/tissues related to Tongue Cancer:

38
Tongue, Tonsil, Lung, Lymph Node, Liver, Endothelial, Brain

Publications for Tongue Cancer

Articles related to Tongue Cancer:

(show top 50) (show all 502)
# Title Authors Year
1
Distribution of cervical metastasis in tongue cancer: Are occult metastases predictable? A retrospective study of 117 oral tongue carcinomas. ( 29174473 )
2018
2
Effect of induction chemotherapy on the quality-of-life in patients with advanced stage tongue cancer by a prospective study. ( 29332408 )
2018
3
Angiogenesis and evading immune destruction are the main related transcriptomic characteristics to the invasive process of oral tongue cancer. ( 29386520 )
2018
4
Simple laryngeal suspension procedure by suturing the digastric muscle to the periosteum of the mandible in neck dissection for tongue cancer. ( 29395281 )
2018
5
Survival and recurrence of resectable tongue cancer: Resection margin cutoff value by T classification. ( 28960654 )
2018
6
Classification of tongue cancer resection and treatment algorithm. ( 29432642 )
2018
7
Efficacy of postoperative neck irradiation for regional control in patients with pN0 oral tongue cancer: Propensity analysis. ( 29083541 )
2018
8
Cancer-associated i-8broblasts confer cisplatin resistance of tongue cancer via autophagy activation. ( 29156523 )
2018
9
Long noncoding RNA Lnca89EGFR promotes cell proliferation and inhibits cell apoptosis via regulating the expression of EGFR in human tongue cancer. ( 29138845 )
2018
10
Effects of low-intensity ultrasound combined with low-dose carboplatin in an orthotopic hamster model of tongue cancer: A preclinical study. ( 29436690 )
2018
11
Functional evaluation of swallowing in patients with tongue cancer before and after surgery using high-speed continuous magnetic resonance imaging based on T2-weighted sequences. ( 29128287 )
2018
12
Isolated huge right ventricular tumor: cardiac metastasis of tongue cancer. ( 29036783 )
2017
13
Decellularized tongue tissue as an in vitro model for studying tongue cancer and tongue regeneration. ( 28600128 )
2017
14
Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. ( 28900608 )
2017
15
Notch1 regulates tongue cancer cells proliferation, apoptosis and invasion. ( 29117785 )
2017
16
In vitro study on anti-cancer properties of genistein in tongue cancer. ( 29180873 )
2017
17
Targeted sequencing of tonsillar and base of tongue cancer and human papillomavirus positive unknown primary of the head and neck reveals prognostic effects of mutated FGFR3. ( 28525363 )
2017
18
Kikuchi-Fujimoto disease in the regional lymph nodes with node metastasis in a patient with tongue cancer: A case report and literature review. ( 28693162 )
2017
19
Bacteriome and mycobiome associations in oral tongue cancer. ( 29228609 )
2017
20
Expression of von Hippel-Lindau tumor suppressor protein (pVHL) characteristic of tongue cancer and proliferative lesions in tongue epithelium. ( 28549422 )
2017
21
Long non-coding RNA MALAT1 interacts with miR-124 and modulates tongue cancer growth by targeting JAG1. ( 28260102 )
2017
22
Contrast - enhanced ultrasound mapping of sentinel lymph nodes in oral tongue cancer - a pilot study. ( 28045344 )
2017
23
Swallowing Rehabilitation Affects Period of Hospitalization after Surgery for Tongue Cancer. ( 28381730 )
2017
24
Maternal genetic backgrounds contribute to the genetic susceptibility of tongue cancer patients in Hunan, central of China. ( 28278694 )
2017
25
Histamine H4 receptor signalling in tongue cancer and its potential role in oral carcinogenesisA - a short report. ( 28653289 )
2017
26
Change in reimbursement and costs in German oncological head and neck surgery over the last decade: ablative tongue cancer surgery and reconstruction with split-thickness skin graft vs. microvascular radial forearm flap. ( 29124365 )
2017
27
Intraoperative Ultrasound in Oral Tongue Cancer Resection: Feasibility Study and Early Outcomes. ( 29161194 )
2017
28
Tongue-out versus tongue-in position during Intensity-Modulated Radiotherapy for base of tongue cancer: Clinical implications for minimizing post-Radiotherapy Swallowing Dysfunction. ( 28475284 )
2017
29
Tenascin-C and fibronectin expression divide early stage tongue cancer into low- and high-risk groups. ( 28095396 )
2017
30
Folatea89targeted polymeric micelles loaded with superparamagnetic iron oxide as a contrast agent for magnetic resonance imaging of a human tongue cancer cell line. ( 28944881 )
2017
31
Nomograms to estimate long-term overall survival and tongue cancer-specific survival of patients with tongue squamous cell carcinoma. ( 28411370 )
2017
32
Prognostic significance of gene amplification of ACTN4 in stage I and II oral tongue cancer. ( 28385383 )
2017
33
Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1). ( 28859669 )
2017
34
Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012. ( 28351569 )
2017
35
Edema worsens target coverage in high-dose-rate interstitial brachytherapy of mobile tongue cancer: a report of two cases. ( 28344606 )
2017
36
Improving margin revision: Characterization of tumor bed margins in early oral tongue cancer. ( 29074194 )
2017
37
Cytoplasmic neuropilin 2 is associated with metastasis and a poor prognosis in early tongue cancer patients. ( 28602571 )
2017
38
Bufalin induced apoptosis in SCCa894 human tongue cancer cells by decreasing Bcla892 and increasing Bax expression via the mitochondriaa89dependent pathway. ( 28983595 )
2017
39
Breast Cancer in a Pectoralis Major Myocutaneous Flap Used for the Reconstruction of Tongue Cancer: A Case Report. ( 28434900 )
2017
40
Regional recurrence in early stage I-II oral tongue cancer: a single institutional study and review of the literature. ( 28361597 )
2017
41
E3 ubiquitin ligase, RNF139, inhibits the progression of tongue cancer. ( 28662643 )
2017
42
Changes in the distributions of fluorine-18-labelled fluoro-2-deoxy-D-glucose accumulation into tongue-related muscles after dissection in patients with tongue cancer. ( 28467114 )
2017
43
Evaluation of the budding and depth of invasion (BD) model in oral tongue cancer biopsies. ( 28766010 )
2017
44
Immunohistochemical analysis of EGFR and hyaluronan in tongue cancer and the development of regional recurrence in patients initially diagnosed N0. ( 28355940 )
2017
45
Human papillomavirus and p16 protein expression as prognostic biomarkers in mobile tongue cancer. ( 28669249 )
2017
46
Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for T2-4N0 tongue cancer: control of occult neck metastasis. ( 28434836 )
2017
47
Long-term functional outcomes after resection of tongue cancer: determining the optimal reconstruction method. ( 28748261 )
2017
48
Identification of genes associated with tongue cancer in patients with a history of tobacco and/or alcohol use. ( 28356939 )
2017
49
Survival and Functional Outcome after Treatment for Primary Base of Tongue Cancer: A Comparison of Definitive Chemoradiotherapy versus Surgery Followed by Adjuvant Radiotherapy. ( 29281874 )
2017
50
Effectiveness of radiotherapy+ozone on tumoral tissue and survival in tongue cancer rat model. ( 28390748 )
2017

Variations for Tongue Cancer

Expression for Tongue Cancer

Search GEO for disease gene expression data for Tongue Cancer.

Pathways for Tongue Cancer

Pathways related to Tongue Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 CCND1 CDKN1A CDKN2A MMP2 MMP8 MMP9
2
Show member pathways
12.99 CCND1 CDH1 CDKN1A CDKN2A CTNNB1 MMP9
3
Show member pathways
12.92 CCND1 CDKN1A CTNNB1 PRLR TERT TP53
4
Show member pathways
12.64 CCND1 CDH1 CDKN1A CDKN2A CTNNB1 TERT
5
Show member pathways
12.56 CDKN1A CTNNB1 MMP2 TP53
6
Show member pathways
12.55 CCND1 CDKN1A CTNNB1 MMP9 TP53
7
Show member pathways
12.54 CCND1 CDKN1A CDKN2A TP53
8 12.48 CCND1 CDKN1A CDKN2A TP53
9 12.48 BMI1 CCND1 CDKN1A CDKN2A MMP9 TP53
10
Show member pathways
12.43 CCND1 CDKN1A CDKN2A MMP2 MMP9 TP53
11 12.4 CCND1 CDH1 CTNNB1 TP53
12 12.38 CCND1 CDH1 CDKN1A CDKN2A CTNNB1 MMP2
13 12.36 CCND1 CDKN1A CDKN2A CTNNB1 TERT TP53
14
Show member pathways
12.35 CCND1 CDKN1A CDKN2A TP53
15
Show member pathways
12.34 CCND1 CDKN1A CDKN2A TP53
16 12.33 CCND1 CDH1 CDKN1A CDKN2A TP53
17 12.28 CCND1 CDKN1A CDKN2A TP53
18 12.24 BMI1 CDKN1A MMP9 TP53
19 12.19 CCND1 CDKN1A CTNNB1 MMP2 MMP9 TP53
20 12.16 CCND1 CDKN1A CDKN2A TP53
21 12.14 CCND1 CDH1 CTNNB1 TP53
22
Show member pathways
12.13 CCND1 CDKN1A CDKN2A TP53
23
Show member pathways
12.11 CCND1 CDKN1A CTNNB1 MMP2
24 12.08 CTNNB1 MMP2 MMP9 TP53
25 12.05 CCND1 CDKN1A TERT TP53
26 12.04 CCND1 CDKN1A CDKN2A TP53
27 12.02 CDKN1A CDKN2A CTNNB1 MMP2 TP53
28 11.98 CCND1 MMP9 TP53
29 11.98 CDH1 CTNNB1 MMP2 MMP9
30 11.97 CCND1 CDKN1A CDKN2A CTNNB1 TP53
31 11.96 CCND1 CTNNB1 TP53
32 11.95 CCND1 CDKN1A MMP2 MMP9 TP53
33 11.92 BMI1 CDKN1A CDKN2A TP53
34 11.92 CCND1 CDH1 CDKN1A CTNNB1 MMP2 MMP9
35 11.9 CCND1 CDKN1A CDKN2A CTNNB1 TP53
36 11.89 CCND1 MMP2 VEGFC
37
Show member pathways
11.89 MMP2 MMP8 MMP9
38 11.85 CCND1 CDKN1A TP53
39 11.84 CCND1 CDKN1A CTNNB1
40 11.82 MMP2 MMP9 VEGFC
41 11.82 CCND1 CDKN1A TP53
42 11.77 BMI1 MMP9 TERT TP53
43 11.73 CDKN1A CDKN2A TP53
44 11.66 MMP2 MMP9 TERT
45
Show member pathways
11.66 CCND1 MMP2 MMP9
46 11.63 CCND1 CDH1 CTNNB1 MMP2 MMP9 TERT
47 11.62 CDKN1A CTNNB1 MMP9
48
Show member pathways
11.59 CCND1 MMP2 MMP9
49 11.58 CDKN2A TP53 VEGFC
50 11.55 CCND1 CDKN1A TP53

GO Terms for Tongue Cancer

Cellular components related to Tongue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.26 CCND1 CDKN1A
2 apical junction complex GO:0043296 9.16 CDH1 CTNNB1
3 catenin complex GO:0016342 8.96 CDH1 CTNNB1
4 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Tongue Cancer according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.93 CDKN1A MMP9 PRLR TERT TP53
2 positive regulation of apoptotic process GO:0043065 9.92 CDKN2A CTNNB1 MMP9 TP53
3 negative regulation of cell proliferation GO:0008285 9.89 CDKN1A CDKN2A CTNNB1 TP53 VEGFC
4 response to organic cyclic compound GO:0014070 9.81 CCND1 CDKN1A TP53
5 negative regulation of cell growth GO:0030308 9.79 CDKN1A CDKN2A TP53
6 G1/S transition of mitotic cell cycle GO:0000082 9.77 CCND1 CDKN1A CDKN2A
7 response to organic substance GO:0010033 9.74 CCND1 CDH1 CDKN1A
8 Ras protein signal transduction GO:0007265 9.7 CDKN1A CDKN2A TP53
9 collagen catabolic process GO:0030574 9.69 MMP2 MMP8 MMP9
10 response to hyperoxia GO:0055093 9.63 CDKN1A TP53
11 mammary gland alveolus development GO:0060749 9.62 CCND1 PRLR
12 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.61 CDKN1A TP53
13 embryo implantation GO:0007566 9.61 MMP2 MMP9 PRLR
14 response to corticosterone GO:0051412 9.6 CCND1 CDKN1A
15 entry of bacterium into host cell GO:0035635 9.58 CDH1 CTNNB1
16 morphogenesis of embryonic epithelium GO:0016331 9.58 CTNNB1 VEGFC
17 response to organonitrogen compound GO:0010243 9.58 CCND1 CDKN1A TP53
18 mitotic G1 DNA damage checkpoint GO:0031571 9.56 CCND1 TP53
19 regulation of epithelial cell differentiation GO:0030856 9.55 CTNNB1 PRLR
20 endodermal cell differentiation GO:0035987 9.54 MMP2 MMP8 MMP9
21 response to X-ray GO:0010165 9.5 CCND1 CDKN1A TP53
22 signal transduction by p53 class mediator GO:0072331 9.48 CDKN1A TP53
23 cellular response to indole-3-methanol GO:0071681 9.46 CDH1 CTNNB1
24 extracellular matrix disassembly GO:0022617 9.46 CDH1 MMP2 MMP8 MMP9
25 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.43 MMP2 MMP9 TERT
26 response to drug GO:0042493 9.43 CCND1 CDH1 CDKN1A CTNNB1 TP53 VEGFC
27 replicative senescence GO:0090399 8.92 CDKN1A CDKN2A TERT TP53

Molecular functions related to Tongue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 9.62 CCND1 CDKN2A CTNNB1 TP53
2 metalloendopeptidase activity GO:0004222 9.54 MMP2 MMP8 MMP9
3 protein kinase binding GO:0019901 9.35 CCND1 CDKN1A CDKN2A CTNNB1 TP53
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CDKN1A CDKN2A
5 disordered domain specific binding GO:0097718 8.8 CDKN2A CTNNB1 TP53
6 protein binding GO:0005515 10 BMI1 CCND1 CDH1 CDKN1A CDKN2A CTNNB1

Sources for Tongue Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....